Has AI discovered the next Ozempic? 研究員s in Spain race to 特許 two 工場/植物 抽出するs they think could be the next big thing for 負わせる loss
- Two 無名の 工場/植物s mimic the 負わせる loss results seen in Ozempic 使用者s
- AI ソフトウェア identified which 工場/植物s could be taken as an oral 負わせる loss 麻薬?
- READ MORE:??Wegovy and Ozempic 推定する/予想するd to rake in $100bn in coming years
人工的な 知能?has 暴露するd two 工場/植物s that 供給する the same 負わせる loss results as Ozempic, によれば a new 熟考する/考慮する.
研究員s at the カトリック教徒 University of Murcia in Spain?報告(する)/憶測d that the 工場/植物s 含む/封じ込める 類似の agonists - a 実体 mimicking a hormone 返答 - to those in Ozempic.
AI ソフトウェア 分析するd thousands of natural 構内/化合物s that could 申し込む/申し出 the same 負わせる loss 構成要素s and 結局 狭くするd 負かす/撃墜する two 工場/植物 抽出するs.
研究員s 始める,決める out to find a 工場/植物 代案/選択肢 予定 to many individuals experiencing 味方する 影響s and 回復するing 負わせる once of the prescription 麻薬.
The team also said that not only would the 工場/植物s be easier on the 団体/死体, but they would also be more accessible and cost 効果的な - Ozempic costs about $936 a month.
They are not 指名するing the 工場/植物 抽出するs - which for now have been 指名するd 構内/化合物 A and 構内/化合物 B -?until they 特許 them for a new 負わせる loss 麻薬.?
![Ozempic?s maker, Novo Nordisk, is preparing to release anew drug, amycretin. Early results from the drug?s safety trial suggest it can help users shed weight twice as quickly as Ozempic](https://i.dailymail.co.uk/1s/2024/03/26/20/82068631-13241813-Ozempic_s_maker_Novo_Nordisk_is_preparing_to_release_anew_drug_a-a-78_1711484830939.jpg)
Ozempic’s 製造者, Novo Nordisk, is 準備するing to 解放(する) もう一度 麻薬, amycretin. 早期に results from the 麻薬’s safety 裁判,公判 示唆する it can help 使用者s shed 負わせる twice as quickly as Ozempic
![Weight loss drugs surged last year, with Ozempic taking the lead as the most-used option](https://i.dailymail.co.uk/1s/2024/03/26/20/82923859-13241813-image-a-79_1711485192062.jpg)
負わせる loss 麻薬s 殺到するd last year, with Ozempic taking the lead as the most-used 選択
Ozempic was 解放(する)d in 2017 to 扱う/治療する people with 糖尿病, but was late 設立する to help people?lose 負わせる?by 抑えるing their appetite.?
Since been 布告するd as a '奇蹟 麻薬,' use of it has?by 300 パーセント in いっそう少なく than three years, with prescriptions hitting nine million in the US as of September 2023.?
Morgan Stanley 分析家s have?事業/計画(する)d?that over the next 10 years, 24 million people - seven パーセント of the US 全住民 - will be taking Ozempic or Wegovy.
But 使用者s have 報告(する)/憶測d spats of?nausea and vomiting, along mental health 問題/発行するs like 苦悩 and irritability when taking the 週刊誌 注射s.
To 演説(する)/住所 these 問題/発行するs, scientists 手配中の,お尋ね者 to '焦点(を合わせる) on 工場/植物 抽出するs and other natural 構内/化合物s because they may have より小数の 味方する-影響s' and 選択 s that? could be taken orally rather than an 注射.?
But the 代案/選択肢 needed to?still 活動させる/戦時編成する the GLP-1 (glucagon-like peptide-1) receptor, which is how Ozempic?誘発する/引き起こすs the 団体/死体's 負わせる loss 返答.
![Ozempic can cost as much as $935 per month before health insurance, while the cost overseas hovers around $100 on average](https://i.dailymail.co.uk/1s/2024/03/26/20/82923861-13241813-image-a-80_1711485196839.jpg)
Ozempic can cost as much as $935 per month before health 保険, while the cost overseas hovers around $100 on 普通の/平均(する)
'麻薬s that aren't peptides may have より小数の 味方する 影響s and be easier to 治める, meaning they could be given as pills rather than 注射s,' said Elena Murcia, a co-author of the 熟考する/考慮する and a member of the 構造上の Bioinformatics and High-業績/成果 計算するing 研究 Group (BIO-HPC).